BIAF

Business Context and Reporting Period

Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 10-Q (Unaudited)
Period: Quarter and six months ended June 30, 2024
Business Overview: The Company develops noninvasive diagnostics for early-stage lung cancer (CyPath® Lung) and conducts early-stage therapeutic research. Operations are conducted through two segments: Diagnostic R&D and Laboratory Services (via subsidiary Precision Pathology Laboratory Services, LLC, acquired in September 2023).

Key Financial Metrics

Note: Revenue is primarily driven by patient service fees ($4.2M for six months) from the acquired laboratory operations. Direct costs and expenses were $2.98M for the six-month period.

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased from $20,659 (six months ended June 30, 2023) to $4.8 million (six months ended June 30, 2024). This surge is attributed to the consolidation of the Precision Pathology Laboratory Services (PPLS) acquisition in September 2023.
• Expense Increase: Total operating expenses rose from $3.36 million to $8.84 million for the six-month period.
  • Direct Costs: Increased from $1,322 to $2.98 million due to new laboratory operations.
  • SG&A: Increased from $2.55 million to $4.66 million, driven by acquired administrative costs and expanded sales support.
  • Depreciation/Amortization: Increased from $43,236 to $300,707 due to acquired assets.
• Cash Position: Cash and cash equivalents decreased from $2.82 million (Dec 31, 2023) to $0.80 million (June 30, 2024), reflecting a net cash burn of approximately $3.9 million from operations.

Guidance, Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for at least 12 months following the report date. Despite cash on hand of $0.8 million at period end, operations are projected to be funded only through October 2024 without additional capital.
• Recent Financing (Subsequent Events): On August 2, 2024, the Company raised approximately $1.7 million through warrant exercises and a registered direct offering. Management estimates this extends the runway to November 2024.
• Outlook: The Company expects to continue incurring significant operating losses as it advances clinical trials and commercializes CyPath® Lung. Future profitability depends on raising additional capital and increasing revenue from laboratory services.
• Risks: Key risks include the inability to secure future financing, delays in regulatory approvals (FDA de novo classification), and the high cost of clinical development. The Company is also subject to dilution from outstanding warrants (approx. 8.8 million outstanding).

Investor Verification Checklist

• Liquidity Runway: Verify the sufficiency of the $1.7 million raised in August 2024 to cover operating expenses through November 2024 and the timeline for the next capital raise.
• Revenue Quality: Assess the collectability of the $1.6 million increase in accounts receivable, noting the transition to a new medical billing provider caused temporary delays.
• Warrant Dilution: Review the terms of the 8.8 million outstanding warrants and the recent issuance of new warrants in August 2024, which may significantly dilute existing shareholders upon exercise.
• Regulatory Status: Confirm the progress of the CyPath® Lung test toward FDA de novo classification, as current revenue relies on its status as a Laboratory Developed Test (LDT).
• Acquisition Integration: Monitor the profitability timeline of the PPLS laboratory operations, as the Company currently operates at a loss despite the revenue increase.